Read about the latest advances from the Lady Davis Institute for Medical Research (LDI) and its researchers, including new findings, grant awards, innovations, and collaborations.
Cutting-edge study highlights the role of a new blood test that may help decide who needs chemotherapy in patients with aggressive breast cancer
The research provides new insights into the prognostic value of ctDNA and its ability to guide personalized treatment strategies for patients with triple-negative breast cancer.
New study links GLP-1 receptor agonists to increased risk of gastroesophageal reflux disease (GERD) in type 2 diabetes patients
The study shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which include Ozempic®, Rybelsus® and other widely- prescribed drugs for type 2 diabetes and obesity management, may increase the risk of developing gastroesophageal reflux disease (GERD) and its complications compared to sodium–glucose cotransporter-2 (SGLT-2) inhibitors (such as Brenzavvy™, Invokana®, etc.).
New study reveals promising strategy to retrain neutrophils to target breast cancer
Innovative strategy has the potential to revolutionize the treatment of breast cancer, particularly for patients who have developed resistance to targeted therapies.
